Ritu Salani

1 month ago | onclive.com | Ritu Salani

CommentaryVideoMarch 11, 2025Author(s):Fact checked by:Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies. "We need to think outside the box a little bit.

2 months ago | curetoday.com | Ritu Salani

Dr. Ritu Salani, a board-certified gynecologic oncologist and the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, sat down for an interview with CURE on the topic of cervical cancer.

2 months ago | curetoday.com | Ritu Salani

During January, Cervical Cancer Awareness Month, it is important to bring awareness to the disease’s treatment landscape. A vital aspect of cervical care for patients to be aware of is side effects, and the mitigation of these side effects. In an interview with CURE®, Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cancer — such as immunotherapy or other targeted options — and emphasized the importance of always speaking with your health care team.

Aug 19, 2024 | cancernetwork.com | Ritu Salani

CancerNetwork® spoke with Ritu Salani, MD, about the expanded FDA approval of dostarlimab-gxly (Jemperli) in combination with carboplatin/paclitaxel for patients with primary advanced or recurrent endometrial cancer.

Aug 18, 2024 | cancernetwork.com | Ritu Salani

CancerNetwork® spoke with Ritu Salani, MD, a board-certified gynecologic oncologist and director of gynecologic oncology at the University of California, Los Angeles Health, about other developments in endometrial cancer that have the potential clinical implications. In particular, a mismatch repair proficient (pMMR) TP53 wild-type maintenance strategy and antibody-drug conjugates (ADCs) were discussed.